Tibotec Applies for Traditional Approval of NNRTI Etravirine (Intelence)

Tibotec announced on February 5, 2009 that the company has submitted an application to the U.S. Food and Drug Administration (FDA) for traditional approval for its NNRTI etravirine (Intelence). The application includes 48-week data from 2 Phase 3 studies known as DUET-1 and DUET-2.

Premature Aging of CD4 Cells May Accelerate HIV Disease Progression

Despite extensive research over the past 3 decades, the mechanisms underlying HIV disease progression are still not fully understood. But a report in the January 7, 2009 Journal of Acquired Immune Deficiency Syndromes adds another piece to the puzzle.


Changes in Darunavir (Prezista) Resistance Score after Previous Failure of Boosted Tipranavir (Aptivus) in Multidrug-resistant HIV Patients

Darunavir (Prezista) and tipranavir (Aptivus) are the most recently-approved protease inhibitors. Boosted with low-dose ritonavir (Norvir), they both exhibit activity against multidrug-resistant strains of HIV. However, researchers have not yet clearly defined the optimal sequencing of these 2 antiretroviral agents when used in salvage regimens for highly treatment-experienced patients [1,2].

HIV Mutations Can both Reduce and Enhance Virological Response to Boosted Darunavir (Prezista)

Development of viral resistance to anti-HIV drugs is a potential barrier to long-term treatment success. In the current study, published ahead of print in the January 15, 2009 online edition of the Journal of Antimicrobial Chemotherapy, French researchers sought to identify a pattern of HIV protease gene mutations associated with virological response to regimens containing ritonavir-boosted darunavir (Prezista).

Antiretroviral Treatment Interruption Is Associated with Evidence of Kidney Dysfunction in SMART Study

Evidence continues to accumulate showing that antiretroviral treatment interruption, as evaluated in the large SMART trial, is a potentially risky strategy. A new study, published in the January 2, 2009 issue of AIDS, sheds further light on kidney dysfunction in this setting.

Longer Exposure to NRTIs, especially Stavudine, Increases the Risk of Insulin Resistance in Women with HIV

As people with HIV live longer thanks to effective antiretroviral therapy (ART), cardiovascular disease and long-term metabolic problems are a growing concern, leading researchers to focus on the relationship between these conditions, HIV infection itself, and antiretroviral treatment. As reported in the December 1, 2008 Journal of Acquired Immune Deficiency Syndromes, Phyllis Tien and colleagues looked at factors associated with insulin resistance, which may progress to diabetes and can increase the risk of cardiovascular disease.

Adherence Is Reduced in Patients Who Don't Think They Need Antiretroviral Treatment

Adherence is a key contributor to optimal response to antiretroviral therapy. Many factors influence good or poor adherence, including an individual's perceived need for treatment, according to a study published in the December 1, 2008 Journal of Acquired Immune Deficiency Syndromes.